Abstracts

2022-RA-369-ESGO

CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER 2 YEAR SURVIVAL ANALYSIS

Farah Farazestanian, Mehrdad Kohoori, Azadeh Jafari, Maryamsadat Hosseini. ObandGyn, Shahid Beheshti University of Medical Sciences, Imam Hossein Hp, Tehran, Iran, Islamic Republic of; 2Referral HP, Tehran, Iran, Islamic Republic of; 3Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of

Introduction/Background More than 80% of patients with advanced ovarian cancer present with recurrence within five years. During the last decades, Cytoreductive Surgery plus Hyperthermic Intrapertitoneal Chemotherapy has been introduced as a new protocol for treatment of advanced and or recurrent ovarian cancer. However, there is no consensus on its long-term efficiency, and is still under debate. This study aims to evaluate the effectiveness of Cytoreductive Surgery Plus Hyperthermic Intrapertitoneal Chemotherapy in patients with Advanced Ovarian Cancer in Iran.

Methodology Thirty patients with Stage IIIc and IV advanced Ovarian Cancer underwent cytoreductive surgery plus Hyperthermic Intrapertitoneal Chemotherapy at Jam hospital with a fixed surgical team in Tehran, Iran, from 2019 to 2021. Fourteen patients were new cases, and sixteen of them were recurrent cases. At the end of cytoreductive surgery, by using a Hyperthermic Intrapertitoneal Chemotherapy device, Cisplatin was circulated in the peritoneal cavity for 90 minutes at a dose of 80–100 mg/m2 at 43 °C dti.)

Results Among thirty patients with 54.97±10.74 years of mean age, the mean overall survival was 564.967 days, and 2-year survival rates were 66.7%. According to Fisher’s exact test, there was a statistically significant relationship between disease-free after surgery and mortality rate (p=0.00). However, there was no statistically significant relationship between recurrence after surgery and mortality rate (p=0.093).

Conclusion Cytoreductive surgery plus Hyperthermic Intrapertitoneal Chemotherapy might increase the survival of Advanced Ovarian Cancer patients.

2022-RA-371-ESGO

IMMATURE TERATOMA OF THE OVARY DIAGNOSED AFTER NORMAL DELIVERY: A CASE REPORT

Marjaneh Farazestanian. Ghaem Hospital, Mashhad, Iran, Islamic Republic of

Introduction/Background Immature teratoma is also known as malignant teratoma or teratoblastoma or Embryonal teratoma and includes less than 1% of all teratomas and one third of malignant teratomas. The tumor is uncommon during pregnancy. The aim of this report is to introduce a case of immature teratoma of the ovary diagnosed after normal delivery.

Methodology The patient was a 26 years old woman who had undergone surgery two years ago due to bilateral ovarian cyst and abdominal pain, and the pathology reported the mature cystic teratoma. The patient again referred due to enlarged abdomen following normal delivery. Laparotomy was performed due to large ovarian mass, and salpingo-oophorectomy was performed with report of immature teratoma in frozen section. After the surgery, the patient received four courses of BEP-regimen chemotherapy. Now, the patient is followed-up and tumor markers, sonography and examination of the patient are normal.

Results Given the rare nature of the disease and the importance of early diagnosis of malignant ovarian masses in order to increase the patients’ survival rate, it is necessary to pay more attention to the adnexa in ultrasonography and clinical examinations of pregnant women.

Conclusion Given the rare nature of the disease and the importance of early diagnosis of malignant ovarian masses in order to increase the patients’ survival rate, it is necessary to pay more attention to the adnexa in ultrasonography and clinical examinations of pregnant women.

2022-RA-374-ESGO

PRIMARY OVARIAN NON-HODGKIN’S LYMPHOMA: A CASE REPORT

Laya Shirinzadeh. Ghaem Hospital, Mashhad, Iran, Islamic Republic of

Introduction/Background Non-Hodgkin’s lymphoma in the genital system is uncommon and ovary is one of the most common sites of involvement. Ovarian involvement in non-hodgkin’s lymphoma is often secondary and is a part of the
systemic involvement. Primary and localized ovarian involvement is uncommon and occurs in less than 10% of cases. In this study, a rare case of primary ovarian non-Hodgkin's lymphoma is presented.

**Methodology** The patient was a 64-year-old woman with a history of hysterectomy and postmenopausal bleeding that referred to the academic hospital of Mashhad University of Medical Sciences. On ultrasound and CT scans, solid cystic foci were found between the bladder and rectum, consistent with the location of the cervix and uterus. Subsequent evaluations confirmed histological and immunohistochemical diagnosis of ovarian non-Hodgkin's lymphoma.

**Results** Ovarian lymphoma is one of the differential diagnoses that should be considered in the pelvic masses.

**Conclusion** Ovarian lymphoma is one of the differential diagnoses that should be considered in the pelvic masses.

### Abstracts

#### PROTEOMIC ANALYSIS OF EXOSOMES SECRETED DURING MESENCHYMAL-EPITHELIAL TRANSITION FOR POTENTIAL DIAGNOSIS OF MESENCHYMAL SUBTYPE OF HIGH GRADE OVARIAN SEROUS CARCINOMA

1Germano Aguier Ferreira, 1Carolina Hassibe Thomé, 1Clarice Izumi, 1Mariana Lopes Grassi, 1Guilherme Pauperio Lanfredi, 1Marcus Smolka, 1Vitor Marcel Faça, 1Francisco José Candido dos Reis.

2Department of Cellular and Molecular Biology and Pathogenic Bioagents, Ribeirao Preto Medical School, Ribeirao Preto, Brazil.

Introduction/Background The epithelial-mesenchymal transition (EMT) promotes alterations in cell signaling and morphology, favoring metastatic progression. Exosomes are extracellular vesicles, produced by cells under variable conditions, containing proteins involved in cell-cell communication. Our aim was to evaluate the proteome of exosomes secreted after EMT induction to identify potential biomarkers for ovarian cancer classification.

Methodology EMT was induced in the ovarian cancer cell line CAOV3 using 10 ng/mL EGF for 96 h after 24 h of serum deprivation. Exosomes were isolated from the supernatant of cells under EMT induction and noninduced conditions. The exosome proteins were extracted, identified, and quantified. The proteomic data were integrated by Label-Free-Quantification (LFQ) and classification using integration pattern analysis (PCA) and regression tree (CART).

Results The CAOV3-exosomes obtained during EMT had ~150 nm in diameter and morphology similar to exosomes from nonstimulated CAOV3. The proteomic analysis highlighted 157 proteins differentially detected between EMT induced and nonstimulated CAOV3, 100 up and 57 down accumulated. Integrative analysis of up accumulated proteins with TCGA transcriptomic signature identified PLAU, LAMB1, COL6A1, and TGFBI as potential biomarkers of mesenchymal HGSOC subtype.

Conclusion The combination of EMT induction, exosome isolation, and large-scale proteomic analysis identified potential biomarkers of ovarian cancer aggressiveness. Our data warrant further investigation of the role of PLAU, LAMB1, COL6A1, and TGFBI in ovarian cancer outcomes.

#### TREATMENT AND OUTCOME OF PATIENTS WITH HIGH-GRADE ADVANCED OVARIAN CANCER (AOC) – REAL WORLD DATA OF THE GERMAN QUALITY ASSURANCE PROJECT (QS OVAR OF THE AGO STUDY GROUP)

1Sven Mahner, 2Andreas du Bois, 3Jacobus Pflisterer, 4Felix Hilpert, 5Markus Kerkmann, 6Jalid Sehouli, 7Nikolaus de Gregorio, 8Lars Ch Hanks, 9Florian Heitz, 10Frederik Marmé, 11Linn Lena Wölber, 12Laura Holtmann, 13Gabriele Elser, 14Philipp Harter, AGO Study Group.

1Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany; 2Klinik für Gynäkologie und Gyn. Onkologie, Ev. Kliniken Essen-Mitte, Essen, Germany; 3Zentrum für Gynäkologische Onkologie, Kiel, Germany; 4Onkologisches Therapiezentrum Krankenhaus Jerusalem, Hamburg, Germany; 5MMF Research GmbH, Münster, Germany; 6Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Universitätmedizin Berlin, Charité, Berlin, Germany; 7Frauenklinik, Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany; 8Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie und Geburtshilfe, Campus Lübeck, Lübeck, Germany; 9Universitätsfrauenklinik, Mannheim, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany; 10Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 11AGO Study Group, Wiesbaden, Germany.

Introduction/Background Outcome of patients with AOC depends largely on treatment quality and expertise of treating physicians and centers. To assess treatment reality and quality in Germany, we initiated a nationwide quality assurance program.

Methodology All German hospitals treating patients with AOC were asked to document their patients with primary diagnosis in the third quarters of 2012 and 2016 in a central database. The current analysis focuses on patients with high-grade AOC stage III/IV.

Results In total, 1010 patients with high-grade AOC were documented. This represents 63% of all patients diagnosed in Germany. Median age was 65 years. The majority (774/1010, 76.6%) were diagnosed with stage III/IV disease and 947/1010 (93.8%) had serous, 34 (3.4%) endometrioid and 29 (2.9%) clear cell histology. 915/1010 (90.6%) had primary debulking surgery (PDS). Complete resection was achieved in 434/915 (47.4%) at PDS and in 54/95 (56.8%) at interval debulking surgery (IDS). Median PFS and OS in patients with PDS and complete resection was 29.7 and 63.1 months compared to 16.8 and 30.7 months in patients with residual disease (PFS: HR 0.86, 95% CI 0.73–0.99 and OS: HR 0.79, 95% CI 0.66–0.95). First-line chemotherapy was carboplatin/paclitaxel (TC) in 919/1010 (91%) of the patients, 627 (62%) also received bevacizumab (TCB) and 544 of these (87%) also received bevacizumab maintenance therapy. Median PFS and OS with TCB was 23.3 and 46.2 months and 18.5 and 39.0 months with TC (PFS: HR 0.86, 95% CI 0.73–1.01 and OS: HR 0.79, 95% CI 0.66–0.95).

The rate of complete tumor resection at surgery as well as the use of bevacizumab increased between the two periods.

Conclusion The majority of patients were treated with primary surgery followed by TCB. Outcome was best when complete tumor resection was achieved at primary surgery and patients received combination chemotherapy with maintenance treatment.